 WALTHAM, Mass., Jan. 03, 2023 GLOBE NEWSWIRE -- Dyne Therapeutics, Inc. Nasdaq: DYN, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 10, 2023 at 3:00 p.m. PT 6:00 p.m. ET. 